Xtant Medical Holdings has announced a strategic partnership with B2i Digital aimed at enhancing investor understanding of its orthobiologics platform and long-term value proposition. This initiative is designed to deliver centralized, investor-focused content to both retail and institutional audiences, showcasing Xtant Medical's leadership in regenerative medicine products for orthopedic and neurosurgical applications.
David Shapiro, CEO of B2i Digital, pointed out the timing of this collaboration, noting Xtant Medical's pivotal expansion phase. The company's broad coverage of major orthobiologic categories and its impressive revenue growth trajectory underscore its potential as a standout investment in the medical technology arena. Sean Browne, CEO of Xtant Medical, stressed the partnership's importance in articulating the company's growth narrative and the intrinsic value of its biologics platform to the investment community.
With fiscal year 2024 revenue hitting $117.5 million, a 29% increase from the prior year, Xtant Medical has showcased strong business fundamentals. Its expansive market access, supported by 450 integrated delivery network contracts and a network of more than 670 independent distributors, solidifies its stance in the $2.5 billion U.S. orthobiologics market, a segment of the broader $10.1 billion global spine market.
